. 2022 Feb 7;17(12):5372–5383. doi: 10.1080/21645515.2021.2007710

Table 2.

Adverse events after administration of a first and second dose of M-M-R_II in two-dose studies

Study	Age at first dose	Interval between doses	Adverse event reporting period	Dose	n^a	Concomitantly administered vaccine(s)	Fever (%) ^b	Measles- or rubella-like rash (%)	Injection site reactions (%)
MMR-161 study group⁶⁷	12–15 months	42 days	42 days (4 days for injection site reactions)	1	1,526	Hepatitis A, Varicella (all participants) plus PCV13 (764 participants)	40–42	NR	20
MMR-161 study group⁶⁷	12–15 months	42 days	42 days (4 days for injection site reactions)	2	1,456	None	32–34	NR	15
Senders⁷⁸	12–23 months	~3 months	42 days (5 days for injection site reactions)	1	611	Varicella	10–11	0–2	41
Senders⁷⁸	12–23 months	~3 months	42 days (5 days for injection site reactions)	2	533	Varicella	8–9	0	31–35
Wiedmann¹⁰⁴	12–18 months	2–3 years	42 days (5 days for injection site reactions)	1	1,279	None	9–10	2–3	22–27
Wiedmann¹⁰⁴	12–18 months	2–3 years	42 days (5 days for injection site reactions)	2	373	None	5–7	0–1	42–45

NR, Not reported.

^an indicates number of participants receiving M-M-R_II in each study.

^bData collection methods and the definition of fever differed across the studies.